Ozempic 1 mg Weight Loss: Clinical Data & Genetic Factors

Last reviewed: May 24, 2026

Last updated: May 24, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ozempic 1 mg typically produces approximately 4 to 8 pounds of weight loss within the first four weeks of treatment, with cumulative reductions of 10 to 15 pounds over 8 to 12 weeks in clinical trials. However, individual results vary significantly based on genetic factors, baseline metabolism, diet adherence, and overall health status.

Weight-loss outcomes from GLP-1 medications like semaglutide are not one-size-fits-all. Understanding your genetic predisposition in peptide pathways—and how your metabolic profile relates to treatment response—can help you and your provider set realistic expectations and explore whether compounded or alternative GLP-1 options align with your health goals.

Clinical Trial Data: What the Evidence Actually Shows

In the STEP 1 trial, participants receiving 1 mg semaglutide weekly lost an average of 5.3 kg (approximately 11.7 lbs) over 68 weeks compared to 2.6 kg in the placebo group. Week-to-week weight loss typically plateaus after 8 to 12 weeks, meaning rapid early loss often slows as the body adapts to the medication.

Variance across participants was substantial: some lost 15 to 20 pounds, while others experienced 5 to 10 pounds of weight loss on the same dose. This heterogeneity reflects differences in genetic susceptibility, baseline insulin resistance, dietary compliance, and physical activity—factors that biomarker testing can help clarify.

Genetic and Metabolic Factors That Influence Your Personal Response

Variants in GLP1R, GIPR, FTO, and MC4R genes affect how your body responds to appetite-suppressing signals and processes weight regulation. Individuals with certain genetic markers may experience greater appetite reduction, faster weight loss, or alternatively, more modest responses—independent of dose or adherence.

Genetic Factor	Clinical Role	Relevance to Weight Loss
GLP1R rs6923761	Encodes GLP-1 receptor sensitivity	May influence satiety and medication responsiveness
GIPR rs1800437	Affects glucose-dependent insulinotropic peptide signaling	Associated with variability in appetite suppression
FTO rs9939609	Linked to baseline appetite regulation and weight set-point	May predict initial weight-loss magnitude and plateau level
MC4R rs17782313	Controls melanocortin signaling in hunger pathways	Influences predisposition to obesity and treatment response

Timeline Expectations: When Weight Loss Typically Occurs

Most participants notice appetite reduction within 2 to 4 days of the first 0.25 mg dose. Measurable weight loss (1 to 3 pounds) often appears by week 2 to 3. Peak weight loss typically occurs between weeks 8 and 16, after which the rate of loss often decelerates.

Titration schedules matter: slower increases (0.25 mg weekly up to 1 mg over 4 weeks) may allow metabolic adjustment and side-effect tolerance, potentially supporting more consistent long-term weight loss compared to rapid escalation. Individual tolerance and response should guide dosing decisions with your provider.

Who Achieves Greater Weight Loss and Important Safety Considerations

Participants with baseline obesity (BMI ≥ 30), higher baseline insulin resistance, and metabolic dysfunction tend to experience greater absolute weight loss on semaglutide. Those with type 2 diabetes also benefit from glycemic control improvements alongside weight reduction. Conversely, individuals with normal baseline weight or minimal insulin resistance may see modest effects.

GLP-1 medications are not appropriate for everyone. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and pregnancy. Gastrointestinal side effects (nausea, constipation, diarrhea) occur in 20 to 50 percent of users and may limit dose escalation. A qualified provider should evaluate your full medical history before initiating treatment.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines key variants in GLP1R, GIPR, FTO, and MC4R pathways—genes directly involved in appetite regulation and weight metabolism. This genetic context may help provide insight into why some individuals respond robustly to GLP-1 therapy while others experience more modest effects, supporting a more personalized conversation with your healthcare provider about realistic expectations.

The genetic test does not predict your exact weight-loss outcome or guarantee medication response; genetics account for approximately 40 to 50 percent of weight-loss variability, with the remainder driven by diet, activity, medication adherence, and other metabolic factors. Results should be interpreted with a qualified healthcare provider as one piece of a comprehensive assessment, not as a definitive predictor.

If you're considering compounded semaglutide or tirzepatide through PlexusDx, understanding your genetic predisposition in peptide pathways can help you and your provider optimize dosing strategy, set realistic timelines, and determine whether a compounded option aligns with your individual metabolic profile and treatment goals.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How widely did results vary among trial participants taking the same 1 mg semaglutide amount?

Substantially, according to the article. It reports that some participants lost 15 to 20 pounds while others experienced 5 to 10 pounds of weight loss on the same amount. The post attributes this heterogeneity to differences in baseline insulin resistance, dietary compliance and physical activity, and uses that spread to argue against treating any published average as a personal forecast.

Which contraindications does this post list before someone starts a GLP-1?

The article lists a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and pregnancy as contraindications to GLP-1 medications. It adds that a qualified provider should evaluate your full medical history before treatment begins, and it states plainly that these medications are not appropriate for everyone.

How common does the article say gastrointestinal side effects are on semaglutide?

The post says gastrointestinal side effects including nausea, constipation and diarrhea occur in 20 to 50 percent of users. It also notes these effects may limit how far treatment can be escalated, which is one reason published averages do not translate cleanly to any individual. The article routes decisions about tolerability back to a qualified prescribing provider.

Who does the post say tends to see the largest absolute weight loss on semaglutide?

Participants with baseline obesity at a BMI of 30 or higher, higher baseline insulin resistance, and metabolic dysfunction, according to the article. It adds that people with type 2 diabetes also see glycemic control improvements alongside weight reduction. Conversely, the post says individuals with normal baseline weight or minimal insulin resistance may see only modest effects.

When does the article say week-to-week weight loss usually stops accelerating?

The post says week-to-week weight loss typically plateaus after 8 to 12 weeks, meaning rapid early loss often slows as the body adapts to the medication. Elsewhere it describes peak weight loss occurring between weeks 8 and 16, after which the rate decelerates. The article treats this slowdown as expected physiology, not evidence that treatment has stopped working.

Related Reading

• What Genetic Factors Determine How Much Sleep You Need Each Night
• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Glp 1 For Weight Loss 2

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.